Anupam Rasayan India Limited Reports Strong Financial Performance in Q4 FY23

Surat : Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and year ended March 31, 2022.

Consolidated Financial Highlights for Quarter Ended March 31st, 2023: Operating Revenues at ₹4,800 million in Q4FY23 as compared to ₹3,249 million in Q4FY22 – growth of 48% Y-o-Y. Total Revenues at ₹5,042 million in Q4FY23 as compared to ₹3,169 million in Q4FY22 – growth of 59% Y-o- Y. EBITDA (incl. other revenue) at ₹1,416 million in Q4FY23 as compared to ₹969 million in Q4FY22 – growth of 46% Y-o-Y. Profit After Tax at ₹726 million in Q4FY23 as compared to ₹461 million in Q4FY22 – growth of 58% Y-o-Y.

Consolidated Financial Highlights for Year Ended March 31st, 2023: Operating Revenues at ₹16,019 million in FY23 as compared to ₹10,738 million in FY22 – growth of 49% Y-o-Y. Total Revenues at ₹16,105 million in FY23 as compared to ₹10,811 million in FY22 – growth of 49% Y-o-Y. EBITDA (incl. other revenue) at ₹4,399 million in FY23 as compared to ₹3,121 million in FY22 – growth of 41% Y-o-Y. Profit after Tax at ₹2,168 million in FY23 as compared to ₹1,522 million in FY22 – growth of 42% Y-o-Y.

Speaking on the performance, Mr Anand Desai, Managing Director, Anupan Rasayan commented, “It gives me pleasure to share that we have continued our growth momentum with a 49% YoY revenue growth on the back of new products commercialized during the year as well as steady growth of the organic portfolio.

On the operations part, we continue to focus on adding more value-added products in our basket as well as bringing financial efficiencies. We have already started witnessing the results of the same which is visible in stable margins and improved working capital resulting in strong cash generation of ₹2,440 Mn from operations.

Our strategic investments in infrastructure, people and technology have also started yielding great results which is visible in the growth that we have delivered as well as the new LOIs we have signed where majority of the customers are new clients. We will not stop here and further invest in strengthening and expanding these pillars of growth.

As we stand, we have signed contracts and LOIs of ₹ 54,830 Mn giving us a strong revenue visibility for the coming years. At the same time, we are witnessing a robust traction in customer engagement as we remain in advance stage of discussions with customers across geographies for many niche and high value molecules. All these factors give us a reassurance of sustained robust growth in FY24.”